Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.57 |
| ▸ | CA12 | O43570 | 5/20 | 0.52 |
| ▸ | CA14 | Q9ULX7 | 5/20 | 0.52 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 3/20 | 0.41 |
| ▸ | CA9 | Q16790 | 3/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | MGAM | O43451 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | SI | P14410 | 1/20 | 0.40 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4968131 | 0.86 | TSHR (0.61) | TSHRCA12CA14LMNAKMT2A | |
| SCHEMBL9955449 | 0.82 | TSHR (0.56) | TSHRCA12CA14LMNAKMT2A | |
| SCHEMBL4006668 | 0.82 | TSHR (0.56) | TSHRCA12CA14LMNAKMT2A | |
| SCHEMBL24129382 | 0.81 | TSHR (0.52) | TSHRCA12CA14LMNAKMT2A | |
| SCHEMBL4374105 | 0.80 | TSHR (0.57) | TSHRCA12CA14LMNAKMT2A | |
| SCHEMBL14575726 | 0.79 | KMT2A (0.48) | TSHRCA12CA14LMNAKMT2A | |
| SCHEMBL1621069 | 0.78 | TSHR (0.55) | TSHRCA12CA14LMNAKMT2A | |
| SCHEMBL4448825 | 0.78 | KMT2A (0.33) | TSHRCA12CA14KMT2A | |
| SCHEMBL9270029 | 0.78 | TSHR (0.55) | TSHRCA12CA14LMNAKMT2A | |
| SCHEMBL11922841 | 0.78 | TSHR (0.55) | TSHRCA12CA14LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023211103-A1 | FLUORINATED ALKYL SULFONE COMPOUND, AND NON-AQUEOUS ELECTROLYTE FOR SECONDARY BATTERY AND SECONDARY BATTERY INCLUDING SAME | 주식회사 천보 | 2023-11-02 | — | — | WO | disclosed |
| US-20230233560-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-07-27 | — | — | US | disclosed |
| CN-114981245-A | Tricyclic sulfones as ROR gamma modulators | 百时美施贵宝公司 | 2022-08-30 | — | — | CN | disclosed |
| US-11008312-B2 | Pyridazine derivatives as RORc modulators | GENENTECH, INC. (US) | 2021-05-18 | — | — | US | disclosed |
| US-11008312-B2 | Pyridazine derivatives as RORc modulators | GENENTECH, INC. (US) | 2021-05-18 | — | — | US | disclosed |
| EP-3535255-A1 | PYRIDAZINE DERIVATIVES AS RORC MODULATORS | H. Hoffnabb-La Roche Ag (CH) | 2019-09-11 | — | — | EP | disclosed |
| US-20190263794-A1 | PYRIDAZINE DERIVATIVES AS RORc MODULATORS | GENENTECH, INC. (US) | 2019-08-29 | — | — | US | disclosed |
| US-20190263794-A1 | PYRIDAZINE DERIVATIVES AS RORc MODULATORS | GENENTECH, INC. (US) | 2019-08-29 | — | — | US | disclosed |
| US-20180185364-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2018-07-05 | — | — | US | disclosed |
| US-9849112-B2 | Pyrrole compounds as Granzyme B inhibitors | VIDA THERAPEUTICS INC. (CA) | 2017-12-26 | — | — | US | disclosed |
| EP-1944305-A1 | Quinoline derivatives as phosphodiesterase inhibitors | GLAXO GROUP LIMITED (GB) | 2008-07-16 | — | — | EP | disclosed |
| US-20080075960-A1 | CURABLE COMPOSITIONS AND BIOFILM-RESISTANT COATINGS THEREFROM | 3M INNOVATIVE PROPERTIES COMPANY | 2008-03-27 | — | — | US | disclosed |
| EP-1633748-B1 | QUINOLINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS | GLAXO GROUP LTD (GB) | 2008-03-05 | — | — | EP | disclosed |
| US-20070142373-A1 | Quinoline derivatives as phosphodiesterase inhibitors | GLAXO GROUP LIMITED (GB) | 2007-06-21 | — | — | US | disclosed |
| US-20070142373-A1 | Quinoline derivatives as phosphodiesterase inhibitors | GLAXO GROUP LIMITED (GB) | 2007-06-21 | — | — | US | disclosed |
| US-20070049570-A1 | Quinoline derivatives as phosphodiesterase inhibitors | DEAN ANTHONY W | 2007-03-01 | — | — | US | disclosed |
| US-20070049570-A1 | Quinoline derivatives as phosphodiesterase inhibitors | DEAN ANTHONY W | 2007-03-01 | — | — | US | disclosed |
| EP-1084123-A1 | NOVEL ASYMMETRICALLY SUBSTITUTED XANTHINE DERIVATIVES, METHOD FOR PRODUCING THEM AND THEIR USE AS MEDICAMENTS WITH AN ADENOSINE-ANTAGONISTIC EFFECT | Boehringer Ingelheim Pharma KG (DE) | 2001-03-21 | — | — | EP | disclosed |
| US-6187780-B1 | ANTIDEPRESSANTS, ANTIASTHMATIC AGENTS; MIGRAINE | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2001-02-13 | — | — | US | disclosed |
| WO-1999054331-A1 | NOVEL ASYMMETRICALLY SUBSTITUTED XANTHINE DERIVATIVES, METHOD FOR PRODUCING THEM AND THEIR USE AS MEDICAMENTS WITH AN ADENOSINE-ANTAGONISTIC EFFECT | BOEHRINGER INGELHEIM PHARMA KG (DE) | 1999-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11008312-B2 | Pyridazine derivatives as RORc modulators | RORC, RORB, RORA | TSHR 123/4885CA12 3595/4885CA14 4618/4885 |
| US-20180185364-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1B, SLC26A4 | TSHR 1187/4885CA12 4114/4885CA14 4465/4885 |
| US-20230233560-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1B, SLC26A4 | TSHR 1187/4885CA12 4114/4885CA14 4465/4885 |
| US-20190263794-A1 | PYRIDAZINE DERIVATIVES AS RORc MODULATORS | RORC, RORB, RORA | TSHR 123/4885CA12 3595/4885CA14 4618/4885 |
| US-20070049570-A1 | Quinoline derivatives as phosphodiesterase inhibitors | PDE3B, PDE4B, PDE4A | TSHR 2526/4885CA12 4618/4885CA14 3905/4885 |
| US-20070142373-A1 | Quinoline derivatives as phosphodiesterase inhibitors | PDE3B, PDE4B, PDE4A | TSHR 2526/4885CA12 4618/4885CA14 3905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.